Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study
AbstractBackground Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs).Methods A post hoc analysis was conducted amon...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2256418 |
| _version_ | 1797211814105186304 |
|---|---|
| author | Li Sun Jun Tao Zhijian Han Hao Chen Zhengkai Huang Zijie Wang Shuang Fei Chuanjian Suo Xiaobing Ju Ruoyun Tan Min Gu |
| author_facet | Li Sun Jun Tao Zhijian Han Hao Chen Zhengkai Huang Zijie Wang Shuang Fei Chuanjian Suo Xiaobing Ju Ruoyun Tan Min Gu |
| author_sort | Li Sun |
| collection | DOAJ |
| description | AbstractBackground Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs).Methods A post hoc analysis was conducted among the subjects in our previous randomized clinical trial (NCT02839941). Forty-three KTRs completing bone metabolism 52 weeks after enrollment were selected for this analysis, among whom 27 patients received VC examinations. In the iguratimod group, iguratimod (25 mg twice daily) was added adjuvant to the traditional triple regimen. At the 52-week follow-up, the following parameters were assessed: serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP), osteocalcin, type I collagen N-terminal peptide (NTx), type I collagen C-terminal peptide (CTx), bone mineral density (BMD) of the femoral neck and lumbar spine, coronary artery calcification (CAC) and thoracic aortic calcification (TAC). Bone metabolic and VC indices were compared between the two groups using the independent samples t test and Wilcoxon nonparametric test.Results At 52 weeks after enrollment, the iguratimod group had lower osteocalcin (p = 0.010), BALP (p = 0.015), NTx (p = 0.007), CTx (p = 0.012), CAC (p = 0.080) and TAC scores (p = 0.036) than the control group. There was no significant difference in serum calcium, phosphorus, 25-hydroxyvitamin D, iPTH and BMD between the groups. Iguratimod could reduce bone turnover markers (BTMs) at both high and low iPTH levels. The adverse effect of iguratimod was mild and tolerable.Conclusion Iguratimod is safe, can reduce BTMs and may could attenuate VC in the first year after KT. |
| first_indexed | 2024-03-11T14:28:16Z |
| format | Article |
| id | doaj.art-77df26ea3d2045f0bd976e5650cf163b |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-04-24T10:32:28Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-77df26ea3d2045f0bd976e5650cf163b2024-04-12T14:34:28ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492023-12-0145210.1080/0886022X.2023.2256418Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary studyLi Sun0Jun Tao1Zhijian Han2Hao Chen3Zhengkai Huang4Zijie Wang5Shuang Fei6Chuanjian Suo7Xiaobing Ju8Ruoyun Tan9Min Gu10Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaAbstractBackground Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs).Methods A post hoc analysis was conducted among the subjects in our previous randomized clinical trial (NCT02839941). Forty-three KTRs completing bone metabolism 52 weeks after enrollment were selected for this analysis, among whom 27 patients received VC examinations. In the iguratimod group, iguratimod (25 mg twice daily) was added adjuvant to the traditional triple regimen. At the 52-week follow-up, the following parameters were assessed: serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP), osteocalcin, type I collagen N-terminal peptide (NTx), type I collagen C-terminal peptide (CTx), bone mineral density (BMD) of the femoral neck and lumbar spine, coronary artery calcification (CAC) and thoracic aortic calcification (TAC). Bone metabolic and VC indices were compared between the two groups using the independent samples t test and Wilcoxon nonparametric test.Results At 52 weeks after enrollment, the iguratimod group had lower osteocalcin (p = 0.010), BALP (p = 0.015), NTx (p = 0.007), CTx (p = 0.012), CAC (p = 0.080) and TAC scores (p = 0.036) than the control group. There was no significant difference in serum calcium, phosphorus, 25-hydroxyvitamin D, iPTH and BMD between the groups. Iguratimod could reduce bone turnover markers (BTMs) at both high and low iPTH levels. The adverse effect of iguratimod was mild and tolerable.Conclusion Iguratimod is safe, can reduce BTMs and may could attenuate VC in the first year after KT.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2256418Kidney transplantationiguratimodchronic kidney diseasemineral and bone disordersvascular calcification |
| spellingShingle | Li Sun Jun Tao Zhijian Han Hao Chen Zhengkai Huang Zijie Wang Shuang Fei Chuanjian Suo Xiaobing Ju Ruoyun Tan Min Gu Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study Renal Failure Kidney transplantation iguratimod chronic kidney disease mineral and bone disorders vascular calcification |
| title | Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study |
| title_full | Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study |
| title_fullStr | Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study |
| title_full_unstemmed | Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study |
| title_short | Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study |
| title_sort | efficacy of iguratimod on mineral and bone disorders after kidney transplantation a preliminary study |
| topic | Kidney transplantation iguratimod chronic kidney disease mineral and bone disorders vascular calcification |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2256418 |
| work_keys_str_mv | AT lisun efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT juntao efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT zhijianhan efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT haochen efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT zhengkaihuang efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT zijiewang efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT shuangfei efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT chuanjiansuo efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT xiaobingju efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT ruoyuntan efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy AT mingu efficacyofiguratimodonmineralandbonedisordersafterkidneytransplantationapreliminarystudy |